Biocom Report Highlights California Life Science Industry’s $394 Billion Economic Impact and Resilience in 2025
Biocom, the largest life science membership association representing companies across California and other major life science markets, has released its 2026 Life Science Economic Impact Report, offering a detailed view of the economic power, investment trends, workforce scale, and innovation momentum shaping one of California’s most influential industries. Developed in partnership with UC San Diego and HSBC Innovation Banking, the report underscores the continued importance of the life science sector to the state’s economy, even as companies navigate funding constraints, regulatory complexity, shifting policy priorities, and intensifying global competition.
According to the report, California’s life science industry generated $394 billion in total economic output in 2025, supported more than 1.08 million jobs statewide, and attracted $73.1 billion in private investment. These figures reflect the sector’s broad economic footprint and its enduring ability to drive innovation, create high-paying jobs, and attract capital across a wide range of subsectors, from biotechnology and pharmaceuticals to diagnostics, medical devices, and advanced manufacturing.
Biocom’s latest analysis goes beyond traditional industry metrics to explore the broader forces shaping the future of life sciences in California and the United States. In addition to examining employment, wages, research funding, and investment activity, the report looks at emerging trends such as the growing role of artificial intelligence in drug discovery and manufacturing, evolving partnership and licensing strategies, renewed attention to domestic biomanufacturing capacity, and the policy decisions likely to influence U.S. competitiveness in the years ahead.
Taken together, the findings portray a sector that remains a central pillar of California’s economy while also standing at a strategic crossroads. The life science industry continues to generate outsized economic value, but it is doing so in an environment that demands greater agility, capital efficiency, manufacturing readiness, and policy support.
A Broad View of Industry Performance and Future Direction
Biocom’s 2026 report is positioned not simply as a record of economic activity, but as a broader assessment of how the life science sector is evolving. The report highlights a market that continues to produce scientific breakthroughs and commercial growth while adapting to a more complex operating environment.
Tim Scott, president and CEO of Biocom, said California’s life science sector has long been defined by its ability to innovate through uncertainty. He noted that even amid funding pressures, regulatory challenges, and heightened global competition, companies across the state continued to advance breakthrough science, invest in manufacturing, adopt new technologies, and create opportunities for patients. In that sense, the report serves two purposes: it measures the industry’s economic contribution while also documenting the ingenuity and resilience that continue to drive its future.
That dual focus is especially important in the current market. In recent years, the life science industry has faced a series of headwinds, including tighter capital markets, inflationary cost pressures, supply chain constraints, and questions about long-term research funding and domestic manufacturing policy. Yet California’s life science ecosystem remains one of the strongest in the world, supported by a dense network of biotech and medtech companies, academic research institutions, investors, manufacturers, healthcare systems, and specialized talent.
The report suggests that this ecosystem continues to provide a durable foundation for innovation. Even in a more selective funding environment, companies are still launching new ventures, raising capital, expanding operations, and progressing research programs. The data also indicate that manufacturing—an area of growing strategic importance for both industry and policymakers—has become an even more significant component of the state’s life science footprint.
California Life Sciences by the Numbers
One of the report’s clearest messages is the sheer scale of the industry’s contribution to California’s economy. In 2025, life science companies and related organizations generated $394 billion in total economic output, reinforcing the sector’s status as one of the state’s most important drivers of growth and innovation.
Employment remains one of the strongest indicators of that impact. The report found that the industry supported more than 1.08 million jobs across California, including both direct employment within life science organizations and the broader ripple effects created through supply chains, service providers, and induced economic activity. Of those positions, more than 406,000 Californians were directly employed in life sciences, reflecting the substantial workforce required to sustain the state’s leadership in research, development, manufacturing, and commercialization.
The industry also continues to provide high-quality, high-wage employment. According to the report, direct employees in California’s life science sector earned an average annual salary of $192,179, underscoring the sector’s role in supporting highly skilled professional and technical careers. Direct labor income generated by life science organizations reached $65.2 billion, while total labor income supported across the broader California economy amounted to $126.9 billion.
These figures point to the life science industry’s outsized economic multiplier effect. Beyond the scientists, engineers, technicians, and executives directly employed by life science companies, the sector also sustains jobs in construction, logistics, professional services, real estate, information technology, and many other areas that benefit from the presence of a large and active innovation economy.
Private Investment Remains a Critical Engine
The report also highlights California’s continued strength as a destination for private capital, despite a more cautious financing environment across the broader biotech and healthcare markets. In 2025, California life science companies attracted $73.1 billion in private investment, including $20.6 billion in venture capital funding.
This continued flow of investment is a significant signal of confidence in the state’s life science ecosystem. Private capital plays a critical role in advancing early-stage innovation, funding clinical development, scaling commercial infrastructure, and supporting the long path from discovery to product launch. Venture capital, in particular, remains a foundational source of support for emerging biotech, medtech, and diagnostics companies that may operate for years before reaching profitability or commercial scale.
The report suggests that while the financing environment has become more disciplined, investors continue to see California as one of the most attractive regions in the world for life science innovation. That appeal is driven by the state’s concentration of scientific talent, academic research, entrepreneurial activity, and company formation, as well as its long history of producing transformative therapies, tools, and technologies.
Jonathan Norris, managing director at HSBC Innovation Banking, contributed an industry outlook to the report that provides additional perspective on capital markets activity, investment conditions, and the broader financial trends influencing the future of life science innovation. His analysis helps frame the investment data within a larger discussion about how companies are adapting their financing strategies, pursuing partnerships, and navigating an evolving capital environment.
Federal Research Funding Continues to Bolster the Ecosystem
Another key pillar of California’s life science leadership is its continued success in securing federal research support. According to the report, Biocom California remained the largest recipient of funding from the National Institutes of Health (NIH) and the National Science Foundation (NSF), securing $6.26 billion in research support through 9,486 awards.
That level of federal funding is a crucial component of the state’s innovation engine. NIH and NSF grants support foundational scientific research, translational studies, workforce development, and institutional capacity-building at universities, research institutes, hospitals, and other organizations across the state. The discoveries generated through publicly funded research often form the scientific basis for future startup creation, licensing deals, clinical programs, and commercial innovation.
In California, where academic institutions and research centers are deeply integrated with the biotech and medtech ecosystem, public research support plays an especially important role. It helps sustain the discovery pipeline that fuels the next generation of therapies, diagnostics, and medical technologies, while also reinforcing the state’s reputation as a hub for scientific excellence.
Manufacturing Expands Its Role in the California Ecosystem
One of the most notable themes in the report is the growing importance of life science manufacturing within California’s broader industry base. Manufacturing employed 143,572 Californians in 2025 and accounted for more than one-third of all life science jobs in the state, according to the report.
This is a significant indicator of how the sector is evolving. While Biocom California has long been associated with research, venture-backed biotech startups, and early-stage innovation, manufacturing is increasingly becoming a central part of the conversation. The expansion of biomanufacturing, diagnostics production, device manufacturing, and related infrastructure reflects a broader industry push to strengthen supply chains, improve domestic production capacity, and support commercialization within the United States.
The emphasis on manufacturing also aligns with wider national priorities. Policymakers and industry leaders have become more focused on domestic manufacturing resilience in the wake of supply chain disruptions, geopolitical uncertainty, and the growing strategic importance of healthcare and biopharmaceutical production. California’s manufacturing workforce and infrastructure therefore represent both an economic asset and a competitive advantage in an increasingly global market.
The report indicates that Biocom companies across the state are continuing to invest in manufacturing operations even as other parts of the industry adjust to workforce reductions or tighter financing conditions. That suggests that many organizations are thinking not only about discovery and clinical progress, but also about how to build the operational capabilities needed for long-term growth and commercialization.
Industry Growth Continues Despite Headwinds
Biocom’s report also points to continued expansion in the number of life science establishments operating across California. The total number of establishments reached 15,730, representing nearly 2% year-over-year growth despite broader industry challenges.
This increase is significant because it reflects continued company formation and operational expansion even in a difficult market. While some segments of the life science industry have seen restructuring, layoffs, or slower financing activity, the overall California ecosystem remains dynamic. New ventures are still being created, research programs are moving forward, and established companies continue to invest in infrastructure and talent.
Scott emphasized that behind the statistics are the people and organizations working to address some of the world’s most pressing health challenges. Biocom Researchers, entrepreneurs, manufacturers, and innovators all play a role in translating scientific progress into therapies, diagnostics, technologies, and jobs. In his view, the numbers tell an important story about scale and impact, but the companies themselves—and the work they are doing—show why California continues to stand out as a global center of life science innovation.
The Ripple Effect: Innovation Beyond the Numbers
To bring that human and commercial impact to life, the report introduces The Ripple Effect, a collection of stories featuring Biocom member companies and the ways they are translating scientific discoveries into tangible outcomes. These stories are intended to show how innovation in life sciences extends beyond research labs and balance sheets to create real-world value for patients, communities, and the broader economy.
The Biocom examples span breakthrough therapies, diagnostic tools, advanced manufacturing initiatives, and emerging technologies, illustrating how scientific progress can drive multiple layers of impact at once. A single company’s innovation may improve patient care, create specialized jobs, attract investment, generate supplier demand, and strengthen a regional innovation cluster. By highlighting these ripple effects, Biocom is making the case that life science innovation should be understood not only as a scientific endeavor, but also as a broad economic and societal engine.
This framing is especially relevant at a time when policy decisions related to healthcare, manufacturing, research funding, and international competitiveness are increasingly shaping the environment in which life science companies operate. The Biocom report suggests that continued investment in science and innovation is not simply a matter of supporting one industry—it is a strategy for strengthening economic resilience, global leadership, and public health outcomes.
California’s Position as a Global Life Science Leader
Overall, Biocom’s 2026 Life Science Economic Impact Report presents a picture of an industry that remains both economically powerful and strategically essential. With $394 billion in economic output, more than 1.08 million jobs supported, $73.1 billion in private investment, and billions in federal research funding, California’s life science sector continues to stand at the forefront of global innovation.
At the same time, the Biocom report makes clear that this leadership cannot be taken for granted. The future of the industry will be shaped by how effectively companies and policymakers respond to new pressures and opportunities—from AI-driven drug discovery and evolving capital markets to domestic manufacturing priorities and global competition for talent and investment.
Biocom’s message is that California’s life science industry has the scale, expertise, and innovative capacity to continue leading, provided it remains supported by a strong research base, investment ecosystem, policy environment, and manufacturing foundation. The report’s findings suggest that, even in a period of uncertainty, the state’s life science companies are continuing to push forward—creating jobs, attracting capital, advancing science, and delivering technologies that improve lives.
In that sense, the Biocom report is both a scorecard and a strategic signal. It documents the industry’s current impact while also reinforcing why life sciences remain one of California’s most important engines of future growth.
About Biocom
Biocom is the largest life science membership association, representing companies across California and major life science markets worldwide. Founded in 1995, Biocom works to drive innovation and industry competitiveness across the life science ecosystem. Our community includes biotechnology, pharmaceutical, medical device, genomics and diagnostics companies at every stage, as well as research institutions, investors, service providers and emerging technology innovators.
Biocom works on behalf of its members to build meaningful connections and deliver valuable insights through Conferences & Events, expand access to Funding & Partnering opportunities, provide Group Purchasing solutions that drive efficiency and savings, champion Policy & Advocacy that protects and advances innovation, and strengthen talent pipelines through Workforce Development.
Biocom maintains offices in San Diego, Los Angeles and the San Francisco Bay Area, with satellite offices in Sacramento, Washington, D.C., Tokyo and a growing presence in Seattle, bridging regional ecosystems and global markets to strengthen growth.
